2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details
臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05039268 (ClinicalTrials.gov) | November 25, 2021 | 23/8/2021 | 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) | A Phase 2 Open Label Trial of 3K3A-APC in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: 3K3A-APC Protein | Macquarie University, Australia | ZZ Biotech, LLC | Recruiting | 18 Years | 75 Years | All | 16 | Phase 2 | Australia |